European Organisation for Research and Treatment of Cancer - EORTC: Urinary Bladder Neoplasms trials
The registry lists 12 Urinary Bladder Neoplasms studies with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor. 1 are open to participants now and 0 have results posted.
Phase 1 1Phase 2 7Phase 3 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder CancerNot yet recruitingNCT06310369Phase 2
- Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial CancerCompletedNCT00623064Phase 1
- Chemotherapy With or Without Surgery in Treating Patients With Bladder CancerTerminatedNCT00042887Phase 3
- Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder UrotheliumCompletedNCT00028756Phase 3
- BCG With or Without Mitomycin in Treating Patients With Bladder CancerCompletedNCT00023842Phase 2
- Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract CancerCompletedNCT00022191Phase 3
- Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the UrotheliumCompletedNCT00014274Phase 2/3
- SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary TractCompletedNCT00006351Phase 2
- Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary TractCompletedNCT00006026Phase 2
- Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder CancerTerminatedNCT00003642Phase 2
- Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder CancerTerminatedNCT00003640Phase 2
- Surgery and BCG in Treating Patients With Bladder CancerCompletedNCT00002990Phase 3